Patients with rare bone cancer still have low survival rates
the ONA take:
Mesenchymal chondrosarcoma remains classified among the more deadly cancer types, but a recent study has indicated that survival for this disease may not be as low as was previously thought.
A Loyola University Medical Center study, led by senior author Lukas Nystrom, MD, reviewed survival for 205 individuals with mesenchymal chondrosarcoma (cases occurring between 1973 and 2011).
Data was sourced from the Surveillance, Epidemiology and End Results (SEER) program database, which is administered through the National Cancer Institute (NCI). Fifty-one percent survived a minimum of 5 years, and 43 percent survived 10 years or more. survival rates observed differed, depending on the tumor location: an axial location demonstrated a lower survival rate.
Dr. Nystrom has suggested that this lower survival outcome could be attributable to the inoperable location of the axial tumors.
Improved screening techniques and technology could be a factor in the lowering (if still high) mortality rates overall.
Mesenchymal chondrosarcoma remains classified among the more deadly cancer types.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|